2024 NOSCM | Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
Overview
NA
Target Audience
NA
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Lajos Puzstai, MD, DPhil, FASCO
Date of Release
May 14th, 2025
-1750785566843.webp&w=3840&q=75)
